Home Page>Media>text

Yifan Pharmaceutical Featured in the 2022 Top 100 List of Chinese Pharmaceutical Innovative Enterprises (CPIE 100)


Yifan Pharmaceutical, an innovative R&D and production company focusing on the pharmaceutical and health sectors, is featured into “2022 Top 100 List of Chinese Pharmaceutical Innovative Enterprises (CPIE 100)”, and “Top 50 List of Chinese R&D Pharmaceutical Enterprises”.

Facilitated by The Healthcare Executive, with the data support from Clarivate Derwent™ Patent Analytics, Cortellis™ Competitive Intelligence and Clinical Trial Intelligence, abided by the three dimensions of foundation of innovation, process of innovation and achievements of innovation, as well as the four index number of authorized patents, patent citations, clinical trials and approved/marketed biologic products, the whole selection process went through 4 months of data screening, integration, and analysis. The selection aimed to tap the power of innovation, spread the experience, and deeply analyze the innovation and sustainability of Chinese pharmaceutical industry. Among them, "Top 50 List of Chinese R&D Pharmaceutical Enterprises" was held for the first time.

Yifan has been adhered to the medium and long-term strategic goal of "innovation” and” internationalization", continued to increase the intensity of R&D investment. At present, our company has a total number of more than 800 R&D personnel and has obtained more than 300 international and domestic patents, of which 20 are international PCT patents. We have set up five product R&D centers in China and the U.S., preliminarily built a qualified team and an international R&D system meeting practical requirements and established a perfect supporting team responsible for clinical trial and registration applications. The supporting team can undertake the whole process of new drug research from project evaluation and initiation, new drug screening, API and preparation technology research to quality standard formulation, clinical research, registration, and submission for approval, so as to promote early marketing of the products under research.

Previous:Ryzneuta™, Evive Biotech’s first biologic product,approved by China’s NMPA
Next:The Pre-Launch Consultation Meeting on F-627 organized by Evive's Partner Chia Tai Tianqing